Neonc Technologies Holdings, Inc. Share Price

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, including aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. It is developing drug delivery methods to be used in combination with drug candidates. It has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH), which is administered to brain cancer patients via intranasal delivery. Its second lead product, NEO212, is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol, has completed preclinical testing and has received investigational new drug (IND) approval from the United States Food and Drug Administration (FDA).